Updates are available Correction dated 2023-09-27
Click to view Correction: https://doi.org/10.1038/s41467-023-41810-9
-
Authors
Nguyen, Thanh
Sridaran, Dhivya https://orcid.org/0000-0003-4401-8571
Chouhan, Surbhi
Weimholt, Cody
Wilson, Audrey
Luo, Jingqin https://orcid.org/0000-0003-2759-3072
Li, Tiandao https://orcid.org/0000-0003-1650-0555
Koomen, John https://orcid.org/0000-0002-3818-1762
Fang, Bin https://orcid.org/0000-0002-7636-1318
Putluri, Nagireddy
Sreekumar, Arun
Feng, Felix Y. https://orcid.org/0000-0002-0963-7687
Mahajan, Kiran
Mahajan, Nupam P. https://orcid.org/0000-0002-4150-602X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1R01CA208258, 5R01CA227025)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (PC200201)
- License Information
-
More Information
Article History
Received: 8 September 2022
Accepted: 19 May 2023
First Online: 9 June 2023
Change Date: 27 September 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-023-41810-9
Competing interests
: A patent “Inhibitors of ACK1/TNK2 Tyrosine Kinase” (patent no. 9,850,216; 10,017,478 and 10,336,734) covers (R)-9b compound. NPM and KM are named as inventors. These patents have been licensed by TechnoGenesys Inc. KM and NPM are co-founders of TechnoGenesys Inc., own stocks, and serve as consultants for TechnoGenesys Inc. The other authors declare no potential conflicts of interest..
